ClinicalTrials.gg
RecruitingNCT07433075ESSNAIUpdated May 13, 2026

Assessment of the Clinical and Economic Impact of Sim&Size, a Simulation Software for Implantable Devices Used in the Treatment of Intracranial Aneurysms: A Prospective Multicenter Study.

An interventional study of 3D simulation of placement of neurovascular implantable medical device and Manual planning of endovascular procedure in Unruptured Intracranial Aneurysm, sponsored by Sim&Cure. Recruiting at 6 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-13.

Sponsored by Sim&Cure · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
576
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 66 studies in Intracranial Aneurysm with a site in France — 19 open to participants now, 26 under way, 1 of them phase 3. Intracranial Aneurysm · France.

Planned enrollment
5th of 23
576 · median 171
Started
2026
with 5 others
No phase
18 of 66
8 open now
Primary completion
2028-06
later than 11 of 25 live
Registered
64th of 66
by date

Among the 66 studies in Intracranial Aneurysm with a site in France, this one is the 5th largest by planned enrollment of the 23 interventional ones that give a count, is one of 6 that started in 2026, is one of 18 with no phase, reaches primary completion later than 11 of the 25 other live ones, and was the 64th registered.

Intracranial Aneurysm

419 studies on the registry are indexed under Intracranial Aneurysm; 118 are open to participants now.

Browse Intracranial Aneurysm studies →

Open to participants now

19 of the 66 studies in Intracranial Aneurysm with a site in France are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 84 Intracranial Aneurysm studies recruiting now, 50 (60%) set no upper age limit and 15 (18%) stop at 75 or younger; 16 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies in Intracranial Aneurysm with a site in France, or all of them as a file.
02

Study summary

In recent years, endovascular treatment of intracranial aneurysms has seen remarkable growth, now surpassing traditional surgical approaches in terms of frequency of use. However, this transition to endovascular methods is not without its challenges. This type of procedure requires careful selection of the device to be implanted, a decision that is still based on manual two-dimensional measurements. This method is questionable, as it does not always take into account the complexity and specificities of certain aneurysms, where three-dimensional geometry can play a crucial role. As a result, these procedures carry significant risks, such as the need for additional maneuvers to remove or reposition devices, or even deploy another support device, which potentially increases the risk of perioperative complications, the duration of surgery, and the amount of radiation required for imaging. Beyond the impact on the patient, these complications also result in additional costs for the healthcare system, expenses that could likely be avoided if more precise and appropriate tools were used from the outset of the procedure. In this context, optimizing the choice of endovascular devices could have both clinical and economic impacts. Innovative technology such as Sim\&Size, which supports healthcare professionals in their therapeutic decisions and choice of the appropriate endovascular device, should therefore improve the effectiveness and efficiency of endovascular treatments.

Sim\&Size is a Software as a Medical Device (SaMD) intended to provide a 3D view of the final placement of neurovascular implantable medical devices of the following types: flow diverters, intrasaccular devices, stent devices, and coils. It uses an actual image of the patient produced by 3D rotational angiography. It offers physicians the possibility of simulating the deployment of implantable medical devices in the artery to be treated and predicts the final placement and the extent of apposition of the implant. Sim\&Size has CE marking and FDA clearance.

This study is a prospective, randomized, multicenter study whose main objective is to show that the use of Sim\&Size during the standard endovascular procedure, compared with a standard endovascular procedure without Sim\&Size, reduces both the actual costs of the hospital stay and the rate of perioperative complications.

03

Conditions studied

  • Unruptured Intracranial Aneurysm

Browse trials for

Keywords

  • endovascular
  • 3D simulation
  • healthcare costs
  • intracranial aneurysm
  • software
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged ≥18 years planned to be treated endovascularly for unruptured intracranial aneurysms.
  • Planned implantable device models is available in the Sim\&Size simulation database and used following their approved indications.
  • Affiliated with the French social security system.
  • Signed the information and consent form

Exclusion criteria

Exclusion Criteria:

  • Patients scheduled to undergo endovascular treatment with stents only
  • Patients presenting for treatment of a ruptured aneurysm
  • Patients who have already been treated in the planned deployment area and whose previous treatment presents a potential contact with the new implant.
  • Giant intracranial aneurysm resulting in poor-quality reconstruction in the potential deployment area of the implant during 3DRA acquisition
  • Presence of artifacts on the 3DRA in the potential deployment area of the implant
  • Patients with multiple aneurysms whose treatment is planned during a single procedure and who require separate individual therapeutic strategies. Examples of individual therapeutic strategies excluded from the study: placement of two separate flow diverters without telescopic technique, individual coiling of each aneurysm.
  • Patients for whom pre-planning was performed using Sim\&Cure software prior to patient randomization.
  • Pregnant or breastfeeding women.
  • Patients under guardianship or conservatorship.
  • Emergency situations.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
576 participants (estimated)

Study arms

  • Active comparator
    Manual planning

    Investigator will use manual two-dimensional measurements to assess which neurovascular implantable medical device to use to treat the intracranial aneurysm.

    Other: Manual planning of endovascular procedure

  • Experimental
    Sim&Size planning

    Investigator will use Sim\&Size software, which allows for three dimensional representation of the aneurysm and for simulation of the placement of different types of devices, to support the choice of the neurovascular implantable medical device used to treat the intracranial aneurysm.

    Other: 3D simulation of placement of neurovascular implantable medical device

Interventions

  • Other3D simulation of placement of neurovascular implantable medical device

    Using the Sim\&Size software to obtain a 3D view of the final placement of neurovascular implantable medical devices of the following types: flow diverters, intrasaccular devices, stent devices, and coils, using an actual image of the patient produced by 3D rotational angiography. Used in the treatment of intracranial aneurysm.

  • OtherManual planning of endovascular procedure

    Manual planning of endovascular procedure using 2D images for placement of implantable medical devices for treatment of intracranial aneurysm.

06

What researchers measure

Primary outcomes

  1. Impact of Sim&Size use during endovascular procedure on healthcare costs

    The main objective is to compare the use of Sim\&Size during a standard endovascular procedure versus manual planning in modifying the healthcare costs of the hospital stay. This objective will be demonstrated through the use of the following criteria: -Difference in average direct hospital costs between the two groups. The two primary outcomes measures will be analyzed in a sequential hierarchical manner

    Time frame: From enrollment to the end of follow-up at 6 months

  2. Impact of Sim&Size use during endovascular procedure on perioperative complications

    The main objective is to compare the use of Sim\&Size during a standard endovascular procedure versus manual planning in modifying the rate of perioperative complications. This objective will be demonstrated through the use of the following criteria: Difference in the rate of perioperative complications. The two primary outcomes measures will be analyzed in a sequential hierarchical manner

    Time frame: From enrollment to the end of follow-up at 6 months

Secondary outcomes

  1. Demonstrate a change in average hospital costs by type of endovascular device used

    Demonstrate a change in average healthcare costs by type of endovascular device used (flow diverter, coils or intra-saccular device)

    Time frame: From enrollment to end of follow-up at 6 months

  2. Demonstrate a change in rate of perioperative complications by type of endovascular device used

    Demonstrate a change in rate of perioperative complications by type of endovascular device used

    Time frame: From surgery to the end of follow-up (6 months)

  3. Change in the rate of aneurysm(s) recurrence

    Demonstrate a change in the rate of aneurysm(s) recurrence at six months. Recurrence is defined as inadequate occlusion of the aneurysm on follow-up imaging at six months.

    Time frame: At 6 months post surgery

  4. Change in operating time

    Demonstrate a change in operating time during the endovascular procedure (in minutes)

    Time frame: From beginning to end of surgery (maximum of 24 hours)

  5. Change of device deployment time

    Demonstrate a change in the device deployment time during the endovascular procedure (in minutes)

    Time frame: From beginning to end of surgery (maximum of 24 hours)

  6. Change in the number of endovascular devices used

    Demonstrate a change in the number of implantable devices used during the endovascular procedure

    Time frame: From beginning to end of surgery (maximum of 24 hours)

  7. Change in the number of wasted implantable devices

    Demonstrate a change in the number of devices opened but not implanted or implanted but removed during the endovascular procedure. An opened device cannot be reused.

    Time frame: From beginning to end of surgery (maximum of 24 hours)

  8. Change in the amount of imaging performed during the endovascular procedure

    Change in the number of angiography and computed tomography imaging series performed during and immediately after deployment

    Time frame: From beginning to end of surgery (maximum of 24 hours)

  9. Change in radiation exposure due to imaging

    Demonstrate a change in radiation exposure (in mGy)

    Time frame: From beginning to end of surgery (maximum of 24 hours)

  10. Change in duration of hospital stay

    Demonstrate a modification of the duration of hospital stay (in days) from entering the hospital to exiting the hospital.

    Time frame: From entering the hospital to exiting the hospital (maximum of 1 month)

  11. Change in the number of intensive care unit transfers/stays

    Demonstrate a change in the number of intensive care unit transfers/stays after the surgery

    Time frame: From the surgery to the end of the follow-up at 6 months

  12. Description of decreased healthcare costs linked to the use of Sim&Size

    Qualitative and quantitative analysis of hospital resources saved through the use of Sim\&Size

    Time frame: From enrollment to the end of follow-up at 6 months

  13. Cost/consequence analysis of the use of Sim&Size

    Carry out a cost/consequences analysis to compare the difference in costs observed in the main criterion with the multiple clinical consequences for the patient.

    Time frame: From enrollment to the end of follow-up at 6 months

07

Study locations

3 of 6 sites recruiting
08

References and documents

Publications

  • Cagnazzo F, Marnat G, Ferreira I, Daube P, Derraz I, Dargazanli C, Lefevre PH, Gascou G, Riquelme C, Morganti R, Berge J, Gariel F, Barreau X, Costalat V. Comparison of Woven EndoBridge device sizing with conventional measurements and virtual simulation using the Sim&Size software: a multicenter experience. J Neurointerv Surg. 2021 Oct;13(10):924-929. doi: 10.1136/neurintsurg-2020-017060. Epub 2020 Dec 23. PubMed 33361275 ↗
  • Piergallini L, Cagnazzo F, Conte G, Dargazanli C, Derraz I, Lefevre PH, Gascou G, Mantilla D, Riquelme C, Bonafe A, Costalat V. Virtual simulation with Sim&Size software for Pipeline Flex Embolization: evaluation of the technical and clinical impact. J Neurointerv Surg. 2020 Oct;12(10):968-973. doi: 10.1136/neurintsurg-2020-015813. Epub 2020 Feb 28. PubMed 32111727 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Jun 2028, 26 months after the start.

Of 47 industry-sponsored interventional studies with no phase under Intracranial Aneurysm, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 49. This study's planned 26 months is close to that.

Counting every sponsor, half of 106 studies reached it within 39 months; a quarter within 22 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2026
First posted
Feb 25, 2026
StartActual
Apr 10, 2026
Primary completionEst.
Jun 2028
CompletionEst.
Jun 2028
Last update
May 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07433075
Lead sponsor
Sim&Cure
Responsible party
Sponsor
First posted
Feb 25, 2026
Start date
Apr 10, 2026
Primary completion
Jun 2028 (estimated)
Completion
Jun 2028 (estimated)
Last update
May 13, 2026

Study contacts

Amandine RENE
Contact
a.rene@sim-and-cure.com
+33783477287

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion